Company CVAbout Strides Pharma Science Ltd 
Strides Pharma Science Ltd
Small Cap
Pharmaceuticals & Biotechnology
Strides Pharma Science Limited was originally incorporated under the name 'Strides Arcolab Limited ' on June 28, 1990. In FY 2016, Shasun Pharmaceuticals Limited merged with Strides Arcolab Limited forming a new identity 'Strides Shasun Limited', which became effective from 19 November, 2015 and name of the Company was changed to 'Strides Pharma Science Limited' from 'Strides Shasun Limited' effective on July 18, 2018.
Company Coordinates
Company Details
No 201 Devavrata Sector 17, Vashi Navi Mumbai Maharashtra : 400703
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 91.96 Cr
Number of Shares
9.2 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
29-Jul-2024
9.2
91.96
41500
10
Issued under ESOP Scheme
22-May-2024
9.19
91.92
7000
10
Issued under ESOP Scheme
29-Apr-2024
9.19
91.91
10000
10
Issued under ESOP Scheme
30-Jan-2024
9.19
91.90
14000
10
Issued under ESOP Scheme
30-Oct-2023
9.19
91.89
5350
10
Issued under ESOP Scheme
25-Oct-2023
9.19
91.88
1197510
10
Conversion of Warrants
20-Oct-2023
9.07
90.68
350000
10
Conversion of Warrants
07-Jul-2023
9.03
90.33
30150
10
Issued under ESOP Scheme
14-Nov-2022
9.03
90.30
12500
0
Issued under ESOP Scheme
14-Nov-2022
9.03
90.30
12500
10
Issued under ESOP Scheme
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
44.1253
Mutual Funds
Held by 9 Schemes (8.48%)
FIIs
Held by 242 FIIs (28.51%)
Promoter with highest holding
Pronomz Ventures Llp (19.58%)
Highest Public shareholder
Quant Mutual Fund - Quant Multi Cap Fund (5.4%)
Individual Investors Holdings
22.44%
Board of Directors
Management
Designation
Remuneration
Arun Kumar
Chairperson & M D
6.0 cr
S Sridhar
Non-Exec. & Independent Dir.
22.0 lacs
Bharat D Shah
Non-Exec. & Independent Dir.
22.0 lacs
Manjula Ramamurthy
Company Sec. & Compli. Officer
0
Homi Rustam Khusrokhan
Non-Exec. & Independent Dir.
22.0 lacs
Badree Komandur
Executive Director (Finance)
4.4 cr
Kausalya Santhanam
Non-Exec. & Independent Dir.
22.0 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Goods
1,356.43
88.23%
Other Operating Revenue - Sale of Intellectual Property Rights
81.94
5.33%
Other Operating Revenue - Export Incentives
30.40
1.98%
Pharmaceutical Goods
Pharmaceutical Goods
Other Operating Revenue - Sale of Intellectual Property Rights
Other Operating Revenue - Sale of Intellectual Property Rights
Other Operating Revenue - Export Incentives
Other Operating Revenue - Export Incentives
Stock DNARevenue and Profits:
Net Sales:
1,221 Cr
(Quarterly Results - Sep 2025)
Net Profit:
128 Cr
Pharmaceuticals & Biotechnology
INR 8,113 Cr (Small Cap)
19.00
34
0.45%
0.59
15.82%
2.97
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
